日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細

  Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters

Valet, G., Repp, R., Link, H., Ehninger, A., & Gramatzki, M. (2003). Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters. Cytometry Part B-Clinical Cytometry, 53B(1), 4-10.

Item is

基本情報

表示: 非表示:
資料種別: 学術論文
その他のタイトル : Cytom. Part B-Clin. Cytom.

ファイル

表示: ファイル

関連URL

表示:

作成者

表示:
非表示:
 作成者:
Valet, G.1, 著者           
Repp, R., 著者
Link, H., 著者
Ehninger, A., 著者
Gramatzki, M., 著者
所属:
1Former Research Groups, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565145              

内容説明

表示:
非表示:
キーワード: acute myeloid leukemia (AML); predictive medicine; personalized medicine; clinical cytomics; data sieving; medical bioinformatics
 要旨: Background: The goal of this study concerned the pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients by data pattern analysis from flow cytometric immunophenotype, cytogenetic, and clinical data. Methods: Sixty-seven parameters of AML patients at diagnosis were classified for predictive information by algorithmic data sieving using iteratively self optimizing triple matrix data pattern analysis (http://www.biochem.mpg.de/valet/classif1.html). Results: Pretherapeutic predictive values for nonsurvival within five years and two years were 100.0% and 83.2%, respectively, compared to 13.9% and 47.4% for the prediction of survival at five years and two years, respectively. At diagnosis, five-year nonsurvivors showed increased patient age and higher concentration of cells in the analyzed specimen, as well as increased levels of % CD2, CD4, CD13, CD36, and CD45 positive AML blasts. Two-year nonsurvivors were characterized by a data pattern of increased patient age and levels of % CD4, CD7, CD11b, CD24, CD45, TH126, and HLA-DR positive AML blasts and decreased levels of % CD1, CD65, CD95, and TC25 positive AML blasts. Cytogenetic abnormalities were not selected for the optimized discriminatory data patterns. Conclusions: The comparatively accurate pretherapeutic identification of high- risk AML patients may prove useful for the development of individualized therapy protocols in stratified clinical patients groups. (C) 2003 Wiley-Liss, Inc.

資料詳細

表示:
非表示:
言語: eng - English
 日付: 2003-05
 出版の状態: 出版
 ページ: -
 出版情報: -
 目次: -
 査読: 査読あり
 識別子(DOI, ISBNなど): eDoc: 41379
ISI: 000182718100002
 学位: -

関連イベント

表示:

訴訟

表示:

Project information

表示:

出版物 1

表示:
非表示:
出版物名: Cytometry Part B-Clinical Cytometry
  出版物の別名 : Cytom. Part B-Clin. Cytom.
種別: 学術雑誌
 著者・編者:
所属:
出版社, 出版地: -
ページ: - 巻号: 53B (1) 通巻号: - 開始・終了ページ: 4 - 10 識別子(ISBN, ISSN, DOIなど): ISSN: 0196-4763